BCRX Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -135.28%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.40, signalling upside risk potential of 159.87%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 273.3%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than BioCryst Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than BioCryst Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.82x versus 2.93x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of 21.47%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.40, signalling upside risk potential of 159.87%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Johnson & Johnson quarterly revenues of $24B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is lower than Johnson & Johnson's net income of $5.2B. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.82x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -287.29%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Novavax, Inc.'s return on equity of --.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.40, signalling upside risk potential of 159.87%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 85.19%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Novavax, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Novavax, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than Novavax, Inc. quarterly revenues of $70.4M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.82x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viatris, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -3.41%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Viatris, Inc.'s return on equity of -21.75%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.40, signalling upside risk potential of 159.87%. On the other hand Viatris, Inc. has an analysts' consensus of $12.1250 which suggests that it could grow by 11.85%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Viatris, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Viatris, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Viatris, Inc. has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.721%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris, Inc. offers a yield of 4.43% to investors and pays a quarterly dividend of $0.12 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viatris, Inc. pays out 90.63% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Viatris, Inc. quarterly revenues of $3.8B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Viatris, Inc.'s net income of -$128.2M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viatris, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.82x versus 0.91x for Viatris, Inc.. Usually stocks with elevated PS ratios are considered overvalued.